Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01094327 · ClinicalTrials.gov registry record
Proteinuria in Pre and Post Transplant
A clinical trial of Proteinuria, sponsored by University of Miami.
- Recruiting
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT01094327 is a study of Proteinuria that is actively recruiting participants, run by University of Miami. The registered enrollment target is 100 participants, below the 196-participant average among 10 other Proteinuria trials with a reported enrollment target (49% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01094327, a study of Proteinuria, is actively recruiting participants, sponsored by University of Miami.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients with focal segmental glomerulosclerosis (FSGS) who progress rapidly to end stage renal disease (ESRD) are at highest risk for development of recurrence of proteinuria following kidney transplantation. This study will look at serum specimens pre and post transplant, as well as kidney transplant specimens pre and post reperfusion to identify where the defects has occured that results in recurrence of proteinuria in a given kidney transplant.
Conditions Studied
Study Locations (1)
Florida
- University of Miami Miller School of Medicine Transplant Clinic - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2008-02 |
| Est. Completion | 2026-11-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01094327
The ClinicalTrials.gov registry entry for NCT01094327 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 196-participant average among 10 other Proteinuria trials with a reported enrollment target (49% lower). The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Proteinuria appearing as the primary indexed condition, and to 0 interventions.
NCT01094327 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT01094327 about?
NCT01094327 is a clinical study titled "Proteinuria in Pre and Post Transplant". Patients with focal segmental glomerulosclerosis (FSGS) who progress rapidly to end stage renal disease (ESRD) are at highest risk for development of recurrence of proteinuria following kidney transplantation. This study will look at serum specimens pre and post transplant, as well as kidney transpl...
What is the current status of trial NCT01094327?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2008-02. Estimated completion is 2026-11-30.
What conditions does trial NCT01094327 study?
This clinical trial studies the following conditions: Proteinuria.
Who is sponsoring clinical trial NCT01094327?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01094327 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Proteinuria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
RECRUITING · Phase 3
-
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
RECRUITING · Phase 2
-
Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis
RECRUITING · Phase 4
-
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
RECRUITING · Phase 3
-
Pilot Study of ACTH in the Treatment of Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
COMPLETED · Phase 3
-
Belatacept Conversion in Proteinuric Kidney Transplant Recipients
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.